Medtronic (NYSE:MDT) Price Target Cut to $86.00 by Analysts at JPMorgan Chase & Co.

Medtronic (NYSE:MDT) had its target price reduced by JPMorgan Chase & Co. from $100.00 to $86.00 in a research note issued to investors on Thursday,MarketScreener reports. The brokerage currently has a “neutral” rating on the medical technology company’s stock. JPMorgan Chase & Co.‘s target price would indicate a potential upside of 4.53% from the stock’s current price.

Other research analysts have also issued research reports about the company. Leerink Partners reduced their price objective on Medtronic from $117.00 to $104.00 and set an “outperform” rating for the company in a research report on Thursday. UBS Group reaffirmed a “neutral” rating and issued a $85.00 target price on shares of Medtronic in a research report on Thursday. Mizuho cut their target price on Medtronic from $120.00 to $100.00 and set an “outperform” rating on the stock in a research note on Wednesday. Truist Financial reduced their price target on shares of Medtronic from $95.00 to $86.00 and set a “hold” rating for the company in a report on Thursday. Finally, Stifel Nicolaus set a $80.00 price target on shares of Medtronic in a research report on Wednesday. Sixteen analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company’s stock. According to MarketBeat, Medtronic presently has a consensus rating of “Moderate Buy” and a consensus price target of $98.45.

Medtronic Stock Performance

NYSE MDT traded up $4.32 during trading hours on Thursday, reaching $82.27. The company’s stock had a trading volume of 2,865,182 shares, compared to its average volume of 9,074,854. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57. The business has a 50-day simple moving average of $81.67 and a 200 day simple moving average of $92.21. Medtronic has a 52 week low of $73.31 and a 52 week high of $106.33. The stock has a market cap of $105.63 billion, a PE ratio of 22.92, a PEG ratio of 1.76 and a beta of 0.58.

Medtronic (NYSE:MDT) last posted its earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 EPS for the quarter, beating the consensus estimate of $1.54 by $0.01. The company had revenue of $9.81 billion during the quarter, compared to analyst estimates of $9.62 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The business’s revenue was up 9.9% compared to the same quarter last year. During the same period in the prior year, the company earned $1.62 earnings per share. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. Equities research analysts predict that Medtronic will post 5.54 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in MDT. Norges Bank acquired a new position in shares of Medtronic during the fourth quarter valued at $1,653,485,000. WCM Investment Management LLC acquired a new stake in Medtronic in the first quarter worth about $965,922,000. Capital Research Global Investors grew its position in Medtronic by 12.6% in the 4th quarter. Capital Research Global Investors now owns 34,573,163 shares of the medical technology company’s stock valued at $3,321,101,000 after buying an additional 3,880,174 shares in the last quarter. Barclays PLC grew its position in Medtronic by 104.6% in the 3rd quarter. Barclays PLC now owns 6,831,203 shares of the medical technology company’s stock valued at $650,604,000 after buying an additional 3,492,192 shares in the last quarter. Finally, Schroder Investment Management Group increased its stake in Medtronic by 78.3% during the 3rd quarter. Schroder Investment Management Group now owns 7,529,849 shares of the medical technology company’s stock valued at $717,143,000 after buying an additional 3,307,211 shares during the period. Institutional investors and hedge funds own 82.06% of the company’s stock.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic reported fiscal Q4 revenue of $9.81 billion and adjusted EPS of $1.55, both ahead of estimates, which reinforced the recent stock move higher.
• Positive Sentiment: Cardiac Ablation Solutions revenue surged 78% globally, helping offset margin pressure and signaling strong demand in a key growth franchise.
• Positive Sentiment: Management lifted its quarterly dividend to $0.72 per share and kept FY2027 growth targets intact, supporting the case for continued operational momentum.
• Positive Sentiment: Medtronic also announced new strategic investments and FDA-related submissions to expand its Hugo robotic-assisted surgery platform, which could add future growth opportunities. Medtronic submits 510(k) filings to expand Hugo robotic-assisted surgery system
• Neutral Sentiment: Several analysts lowered price targets this morning, but most kept constructive ratings such as overweight, outperform, or buy, suggesting valuation concerns rather than a changed bullish thesis.
• Neutral Sentiment: Wells Fargo cut its target to $102 from $114 and Leerink cut to $104 from $117, while Robert W. Baird reduced its target to $85 and kept a neutral rating.
• Negative Sentiment: Medtronic’s FY2027 EPS guidance of $5.90 to $6.00 came in below the consensus estimate, which may temper some of the post-earnings enthusiasm.
• Negative Sentiment: Margins remain a focus as the company flagged tariff and cost headwinds, which could pressure profitability even as sales improve.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).